Search

Your search keyword '"Pawarode, Attaphol"' showing total 315 results
Start Over Author "Pawarode, Attaphol" Search Limiters Available in Library Collection
315 results on '"Pawarode, Attaphol"'

1. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.

Author

Boyiadzis, Michael, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif, Battiwalla, Minoo, Bejanyan, Nelli, Bhatt, Vijaya, Brown, Valerie, Castillo, Paul, Cerny, Jan, Copelan, Edward, Craddock, Charles, Dholaria, Bhagirathbhai, Perez, Miguel, Ebens, Christen, Gale, Robert, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael, Hashmi, Shahrukh, Hildebrandt, Gerhard, Iqbal, Madiha, Jamy, Omer, Kharfan-Dabaja, Mohamed, Khera, Nandita, Lazarus, Hillard, Lin, Richard, Modi, Dipenkumar, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar, Pawarode, Attaphol, Saber, Wael, Sharma, Akshay, Solh, Melhem, Wagner, John, Wang, Trent, Williams, Kirsten, Wirk, Baldeep, Zeidan, Amer, Hourigan, Christopher, Litzow, Mark, Kebriaei, Partow, de Lima, Marcos, Page, Kristin, Weisdorf, Daniel, and Winestone, Lena

Subjects
Adult, Humans, Transplantation, Homologous, Transplantation Conditioning, Neoplasm Recurrence, Local, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Retrospective Studies
Abstract

We investigated the impact of the number of induction/consolidation cycles on outcomes of 3113 adult AML patients who received allogeneic hematopoietic cell transplantation (allo-HCT) between 2008 and 2019. Patients received allo-HCT using myeloablative (MAC) or reduced-intensity (RIC) conditioning in first complete remission (CR) or with primary induction failure (PIF). Patients who received MAC allo-HCT in CR after 1 induction cycle had 1.3-fold better overall survival (OS) than 2 cycles to CR and 1.47-fold better than ≥3 cycles. OS after CR in 2 or ≥3 cycles was similar. Relapse risk was 1.65-fold greater in patients receiving ≥3 cycles to achieve CR. After RIC allo-HCT, the number of induction cycles to CR did not affect OS. Compared to CR in 1 cycle, relapse risk was 1.24-1.41-fold greater in patients receiving 2 or ≥3 cycles. For patients receiving only 1 cycle to CR, consolidation therapy prior to MAC allo-HCT was associated with improved OS vs. no consolidation therapy. Detectable MRD at the time of MAC allo-HCT did not impact outcomes while detectable MRD preceding RIC allo-HCT was associated with an increased risk of relapse. For allo-HCT in PIF, OS was significantly worse than allo-HCT in CR after 1-3 cycles.

Published
2023

3. Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study

Author

Jain, Tania, Estrada-Merly, Noel, Salas, M. Queralt, Kim, Soyoung, DeVos, Jakob, Chen, Min, Fang, Xi, Kumar, Rajat, Andrade-Campos, Marcio, Elmariah, Hany, Agrawal, Vaibhav, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Ballen, Karen, Beitinjaneh, Amer, Bhatt, Vijaya Raj, Bredeson, Christopher, DeFilipp, Zachariah, Dholaria, Bhagirathbhai, Farhadfar, Nosha, Farhan, Shatha, Gandhi, Arpita P., Ganguly, Siddhartha, Gergis, Usama, Grunwald, Michael R., Hamad, Nada, Hamilton, Betty K., Inamoto, Yoshihiro, Iqbal, Madiha, Jamy, Omer, Juckett, Mark, Kharfan-Dabaja, Mohamed A., Krem, Maxwell M., Lad, Deepesh P., Liesveld, Jane, Al Malki, Monzr M., Malone, Adriana K., Murthy, Hemant S., Ortí, Guillermo, Patel, Sagar S., Pawarode, Attaphol, Perales, Miguel-Angel, van der Poel, Marjolein, Ringden, Olle, Rizzieri, David A., Rovó, Alicia, Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Ustun, Celalettin, Verdonck, Leo F., Wingard, John R., Wirk, Baldeep, Bejanyan, Nelli, Jones, Richard J., Nishihori, Taiga, Oran, Betul, Nakamura, Ryotaro, Scott, Bart, Saber, Wael, and Gupta, Vikas

Published
2024
Full Text
View/download PDF

4. Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD

Author

Etra, Aaron, El Jurdi, Najla, Katsivelos, Nikolaos, Kwon, Deukwoo, Gergoudis, Stephanie, Morales, George, Spyrou, Nikolaos, Kowalyk, Steven, Aguayo-Hiraldo, Paibel, Akahoshi, Yu, Ayuk, Francis, Baez, Janna, Betts, Brian C., Chanswangphuwana, Chantiya, Chen, Yi-Bin, Choe, Hannah, DeFilipp, Zachariah, Gleich, Sigrun, Hexner, Elizabeth, Hogan, William J., Holler, Ernst, Kitko, Carrie L., Kraus, Sabrina, Al Malki, Monzr, MacMillan, Margaret, Pawarode, Attaphol, Quagliarella, Francesco, Qayed, Muna, Reshef, Ran, Schechter, Tal, Vasova, Ingrid, Weisdorf, Daniel, Wölfl, Matthias, Young, Rachel, Nakamura, Ryotaro, Ferrara, James L. M., Levine, John E., and Holtan, Shernan

Published
2024
Full Text
View/download PDF

5. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author

Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Al Malki, Monzr, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, Van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, and Weisdorf, Daniel

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cancer, Blood, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

The authors inadvertently included grant numbers OT3HL147741 & U24CA233032, which are grant-specific. This was an oversight on the authors’ part as these grants did not support the research in this publication.

Published
2021

6. Cardiovascular Events After Hematopoietic Stem Cell Transplant: Incidence and Risk Factors

Author

Vasbinder, Alexi, Hoeger, Christopher W., Catalan, Tonimarie, Anderson, Elizabeth, Chu, Catherine, Kotzin, Megan, Xie, Jeffrey, Kaakati, Rayan, Berlin, Hanna P., Shadid, Husam, Perry, Daniel, Pan, Michael, Takiar, Radhika, Padalia, Kishan, Mills, Jamie, Meloche, Chelsea, Bardwell, Alina, Rochlen, Matthew, Blakely, Pennelope, Leja, Monika, Banerjee, Mousumi, Riwes, Mary, Magenau, John, Anand, Sarah, Ghosh, Monalisa, Pawarode, Attaphol, Yanik, Gregory, Nathan, Sunita, Maciejewski, John, Okwuosa, Tochukwu, and Hayek, Salim S.

Published
2023
Full Text
View/download PDF

7. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.

Author

Bejanyan, Nelli, Zhang, Meijie, Bo-Subait, Khalid, Brunstein, Claudio, Wang, Hailin, Warlick, Erica, Giralt, Sergio, Nishihori, Taiga, Martino, Rodrigo, Passweg, Jakob, Dias, Ajoy, Copelan, Edward, Hale, Gregory, Gale, Robert, Solh, Melhem, Kharfan-Dabaja, Mohamed, Diaz, Miguel, Ganguly, Siddhartha, Gore, Steven, Verdonck, Leo, Hossain, Nasheed, Kekre, Natasha, Savani, Bipin, Byrne, Michael, Kanakry, Christopher, Cairo, Mitchell, Ciurea, Stefan, Schouten, Harry, Bredeson, Christopher, Munker, Reinhold, Lazarus, Hillard, Cahn, Jean-Yves, van Der Poel, Marjolein, Rizzieri, David, Yared, Jean, Freytes, Cesar, Cerny, Jan, Aljurf, Mahmoud, Palmisiano, Neil, Pawarode, Attaphol, Bacher, Vera, Grunwald, Michael, Nathan, Sunita, Wirk, Baldeep, Hildebrandt, Gerhard, Seo, Sachiko, Olsson, Richard, George, Biju, de Lima, Marcos, Hourigan, Christopher, Sandmaier, Brenda, Litzow, Mark, Kebriaei, Partow, Saber, Wael, and Weisdorf, Daniel

Subjects
AML, DRI, MDS, Myeloablative, RIC, Adult, Aged, Disease-Free Survival, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Middle Aged, Myelodysplastic Syndromes, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous
Abstract

Compared with reduced-intensity conditioning (RIC), myeloablative conditioning (MAC) is generally associated with lower relapse risk after allogeneic hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). However, disease-specific risk factors in AML/MDS can further inform when MAC and RIC may yield differential outcomes. We analyzed HCT outcomes stratified by the Disease Risk Index (DRI) in 4387 adults (age 40 to 65 years) to identify the impact of conditioning intensity. In the low/intermediate-risk DRI cohort, RIC was associated with lower nonrelapse mortality (NRM) (hazard ratio [HR], .74; 95% confidence interval [CI], .62 to .88; P < .001) but significantly greater relapse risk (HR, 1.54; 95% CI, 1.35 to 1.76; P < .001) and thus inferior disease-free survival (DFS) (HR, 1.19; 95% CI, 1.07 to 1.33; P = .001). In the high/very high-risk DRI cohort, RIC was associated with marginally lower NRM (HR, .83; 95% CI, .68 to 1.00; P = .051) and significantly higher relapse risk (HR, 1.23; 95% CI, 1.08 to 1.41; P = .002), leading to similar DFS using either RIC or MAC. These data support MAC over RIC as the preferred conditioning intensity for patients with AML/MDS with low/intermediate-risk DRI, but with a similar benefit as RIC in high/very high-risk DRI. Novel MAC regimens with less toxicity could benefit all patients, but more potent antineoplastic approaches are needed for the high/very-high risk DRI group.

Published
2021

8. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

Author

Tamari, Roni, McLornan, Donal P., Ahn, Kwang Woo, Estrada-Merly, Noel, Hernández-Boluda, Juan Carlos, Giralt, Sergio, Palmer, Jeanne, Gale, Robert Peter, DeFilipp, Zachariah, Marks, David I., van der Poel, Marjolein, Verdonck, Leo F., Battiwalla, Minoo, Diaz, Miguel Angel, Gupta, Vikas, Ali, Haris, Litzow, Mark Robert, Lazarus, Hillard M., Gergis, Usama, Bashey, Asad, Liesveld, Jane, Hashmi, Shahrukh, Pu, Jeffrey J., Beitinjaneh, Amer, Bredeson, Christopher, Rizzieri, David, Savani, Bipin N., Abid, Muhammad Bilal, Ganguly, Siddhartha, Agrawal, Vaibhav, Ulrike Bacher, Vera, Wirk, Baldeep, Jain, Tania, Cutler, Corey, Aljurf, Mahmoud, Kindwall-Keller, Tamila, Kharfan-Dabaja, Mohamed A., Hildebrandt, Gerhard C., Pawarode, Attaphol, Solh, Melhem M., Yared, Jean A., Grunwald, Michael R., Nathan, Sunita, Nishihori, Taiga, Seo, Sachiko, Scott, Bart L., Nakamura, Ryotaro, Oran, Betul, Czerw, Tomasz, Yakoub-Agha, Ibrahim, and Saber, Wael

Published
2023
Full Text
View/download PDF

9. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author

Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Malki, Monzr Al, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, Weisdorf, Daniel, and Committee of the CIBMTR, Acute Leukemia

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Pediatric Cancer, Transplantation, Childhood Leukemia, Hematology, Cancer, Pediatric, Stem Cell Research, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous, Acute Leukemia Committee of the CIBMTR, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Cytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosis in acute lymphoblastic leukemia (ALL). To examine the prognostic impact of cytogenetic abnormalities on outcomes after allogeneic hematopoietic cell transplantation, we studied 1731 adults with Philadelphia-negative ALL in complete remission who underwent myeloablative or reduced intensity/non-myeloablative conditioning transplant from unrelated or matched sibling donors reported to the Center for International Blood and Marrow Transplant Research. A total of 632 patients had abnormal conventional metaphase cytogenetics. The leukemia-free survival and overall survival rates at 5 years after transplantation in patients with abnormal cytogenetics were 40% and 42%, respectively, which were similar to those in patients with a normal karyotype. Of the previously established cytogenetic risk classifications, modified Medical Research Council-Eastern Cooperative Oncology Group score was the only independent prognosticator of leukemia-free survival (P=0.03). In the multivariable analysis, monosomy 7 predicted post-transplant relapse [hazard ratio (HR)=2.11; 95% confidence interval (95% CI): 1.04-4.27] and treatment failure (HR=1.97; 95% CI: 1.20-3.24). Complex karyotype was prognostic for relapse (HR=1.69; 95% CI: 1.06-2.69), whereas t(8;14) predicted treatment failure (HR=2.85; 95% CI: 1.35-6.02) and overall mortality (HR=3.03; 95% CI: 1.44-6.41). This large study suggested a novel transplant-specific cytogenetic scheme with adverse [monosomy 7, complex karyotype, del(7q), t(8;14), t(11;19), del(11q), tetraploidy/near triploidy], intermediate (normal karyotype and all other abnormalities), and favorable (high hyperdiploidy) risks to prognosticate leukemia-free survival (P=0.02). Although some previously established high-risk Philadelphia-negative cytogenetic abnormalities in ALL can be overcome by transplantation, monosomy 7, complex karyotype, and t(8;14) continue to pose significant risks and yield inferior outcomes.

Published
2020

10. Impact of second primary malignancy postautologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Author

Ragon, Brittany Knick, Shah, Mithun Vinod, D’Souza, Anita, Estrada-Merly, Noel, Gowda, Lohith, George, Gemlyn, de Lima, Marcos, Hashmi, Shahrukh, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Banerjee, Rahul, Saad, Ayman, Hildebrandt, Gerhard C., Mian, Hira, Abid, Muhammad Bilal, Battiwalla, Minoo, Lekakis, Lazaros J., Patel, Sagar S., Murthy, Hemant S., Nieto, Yago, Strouse, Christopher, Badawy, Sherif M., Al Hadidi, Samer, Dholaria, Bhagirathbhai, Aljurf, Mahmoud, Vesole, David H., Lee, Cindy H., Pawarode, Attaphol, Gergis, Usama, Miller, Kevin C., Holmberg, Leona A., Afrough, Aimaz, Solh, Melhem, Munshi, Pashna N., Nishihori, Taiga, Anderson, Larry D., Jr., Wirk, Baldeep, Kaur, Gurbakhash, Qazilbash, Muzaffar H., Shah, Nina, Kumar, Shaji K., and Usmani, Saad Z.

Published
2023
Full Text
View/download PDF

11. Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification

Author

Etra, Aaron, Gergoudis, Stephanie, Morales, George, Spyrou, Nikolaos, Shah, Jay, Kowalyk, Steven, Ayuk, Francis, Baez, Janna, Chanswangphuwana, Chantiya, Chen, Yi-Bin, Choe, Hannah, DeFilipp, Zachariah, Gandhi, Isha, Hexner, Elizabeth, Hogan, William J., Holler, Ernst, Kapoor, Urvi, Kitko, Carrie L., Kraus, Sabrina, Lin, Jung-Yi, Al Malki, Monzr, Merli, Pietro, Pawarode, Attaphol, Pulsipher, Michael A., Qayed, Muna, Reshef, Ran, Rösler, Wolf, Schechter, Tal, Van Hyfte, Grace, Weber, Daniela, Wölfl, Matthias, Young, Rachel, Özbek, Umut, Ferrara, James L.M., and Levine, John E.

Published
2022
Full Text
View/download PDF

12. Allogeneic haematopoietic cell transplantation for extranodal natural killer/T‐cell lymphoma, nasal type: a CIBMTR analysis

Author

Kanate, Abraham S, DiGilio, Alyssa, Ahn, Kwang W, Malki, Monzr Al, Jacobsen, Eric, Steinberg, Amir, Hamerschlak, Nelson, Kharfan‐Dabaja, Mohamed, Salit, Rachel, Ball, Edward, Bashir, Qaiser, Cashen, Amanda, Couriel, Daniel, Diez‐Martin, Jose, Katsanis, Emmanuel, Linhares, Yulia, Mori, Shahram, Nash, Richard, Pawarode, Attaphol, Perales, Miguel‐Angel, Phipps, Colin D, Richman, Carol, Savani, Bipin N, Shapira, Michael Y, Stiff, Patrick, Strair, Roger, Fenske, Timothy S, Smith, Sonali M, Sureda, Anna, Olteanu, Horatiu, and Hamadani, Mehdi

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Adult, Aged, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Lymphoma, Extranodal NK-T-Cell, Male, Middle Aged, Nose Neoplasms, Registries, Retrospective Studies, Salvage Therapy, Survival Analysis, Transplantation, Homologous, Treatment Outcome, Young Adult, extranodal NK/T-cell lymphoma, allogeneic haematopoietic cell transplantation, survival, relapse, non-relapse mortality, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Published
2018

14. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

Author

Nazha, Aziz, Hu, Zhen-Huan, Wang, Tao, Lindsley, R. Coleman, Abdel-Azim, Hisham, Aljurf, Mahmoud, Bacher, Ulrike, Bashey, Asad, Cahn, Jean-Yves, Cerny, Jan, Copelan, Edward, DeFilipp, Zachariah, Diaz, Miguel Angel, Farhadfar, Nosha, Gadalla, Shahinaz M., Gale, Robert Peter, George, Biju, Gergis, Usama, Grunwald, Michael R., Hamilton, Betty, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Kalaycio, Matt, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Majhail, Navneet S., Murthy, Hemant S., Nathan, Sunita, Nishihori, Taiga, Pawarode, Attaphol, Rizzieri, David, Sabloff, Mitchell, Savani, Bipin N., Schachter, Levanto, Schouten, Harry C., Seo, Sachiko, Shah, Nirav N., Solh, Melhem, Valcárcel, David, Vij, Ravi, Warlick, Erica, Wirk, Baldeep, Wood, William A., Yared, Jean A., Alyea, Edwin, Popat, Uday, Sobecks, Ronald M., Scott, Bart L., Nakamura, Ryotaro, and Saber, Wael

Published
2020
Full Text
View/download PDF

15. Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin's lymphoma.

Author

Frame, David G., Geer, Marcus, Kasha, Salena, Markstrom, Denise, Scappaticci, Gianni, Feeney, Tate, Hayduk, Andrew, Mansoor, Hilary M., Oberfeld, Avery, D'Antonio, Hannah, Anand, Sarah, Sung Won Choi, Maciejewski, John, Pawarode, Attaphol, Riwes, Mary Mansour, Tewari, Muneesh, Magenau, John, and Ghosh, Monalisa

Subjects
NON-Hodgkin's lymphoma, T cells, CD19 antigen, CYTOKINE release syndrome, ELECTRONIC health records
Abstract

Introduction: Lymphodepleting chemotherapy (LDC) is critical to CAR T-cell expansion and efficacy. Despite this, there is not a consensus in the literature regarding the optimal LDC regimen, including dose and frequency. Methods: We retrospectively reviewed consecutive patients at a single institution that received LDC prior to treatment with the CD19 directed CAR T-cell products axicabtagene ciloleucel and tisagenlecleucel. Patients treated at our center received fludarabine 30 mg/m2 and cyclophosphamide 500 mg/m2 for 3 consecutive days prior to May 2019. After this timepoint patients routinely received fludarabine 40 mg/m² and cyclophosphamide 500 mg/m² for 2 consecutive days. Clinical data from each cohort were obtained from the electronic medical record and compared for differences in CAR T-cell efficacy and toxicity. Results: From June 2018 to August 2023, LDC was given to 92 patients prior to CD19 directed CAR T-cell therapy for relapsed non-Hodgkin's lymphoma. Twenty-eight patients received a 3-day regimen, and 64 patients received a 2-day regimen. In the total cohort, 75% of patients received axicabtagene ciloleucel and 25% received tisagenlecleucel. The overall response rates in both the 2-day regimen group and the 3-day regimen group were similar (69% vs 75%, p= 0.21) as were the complete response rates (50% vs 54%, p=0.82). There were no significant differences between the 2-day and 3-day regimens for grade 2-4 cytokine release syndrome (55% vs 50%, p=0.82), grade 2-4 immune effector cell associated-neurotoxicity syndrome (42% vs 29%, p=0.25), or time to resolution of neutropenia or thrombocytopenia. The rate of prolonged platelet recovery lasting greater than 60 days was higher with the 3-day regimen (9% vs 27%, p=0.026). Discussion: As the number of patients eligible for CAR T-cell therapy continues to increase, optimizing each component of therapy is necessary. We show that a 2-day regimen of LDC with fludarabine and cyclophosphamide is feasible without significant impact on CAR T-cell efficacy or toxicity. Prospective studies are necessary to further determine the most effective LDC regimen. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

Author

Zhou, Zheng, Nath, Rajneesh, Cerny, Jan, Wang, Hai-Lin, Zhang, Mei-Jie, Abdel-Azim, Hisham, Agrawal, Vaibhav, Ahmed, Gulrayz, Al-Homsi, A. Samer, Aljurf, Mahmoud, Alkhateeb, Hassan B., Assal, Amer, Bacher, Ulrike, Bajel, Ashish, Bashir, Qaiser, Battiwalla, Minocher, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Choe, Hannah, Copelan, Edward, Cutler, Corey, Damlaj, Moussab B., DeFilipp, Zachariah, De Lima, Marcos, Diaz, Miguel Angel, Farhadfar, Nosha, Foran, James, Freytes, César O., Gerds, Aaron T., Gergis, Usama, Grunwald, Michael R., Gul, Zartash, Hamadani, Mehdi, Hashmi, Shahrukh, Hertzberg, Mark, Hildebrandt, Gerhard C., Hossain, Nasheed, Inamoto, Yoshihiro, Isola, Luis, Jain, Tania, Kamble, Rammurti T., Khan, Muhammad Waqas, Kharfan-Dabaja, Mohamed A., Kebriaei, Partow, Kekre, Natasha, Khera, Nandita, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark, Liu, Hongtao, Marks, David I., Martino, Rodrigo, Mathews, Vikram, Mishra, Asmita, Murthy, Hemant S., Nagler, Arnon, Nakamura, Ryotaro, Nathan, Sunita, Nishihori, Taiga, Olin, Rebecca, Olsson, Richard F., Palmisiano, Neil, Patel, Sagar S., Patnaik, Mrinal M., Pawarode, Attaphol, Perales, Miguel-Angel, Politikos, Ioannis, Popat, Uday, Rizzieri, David, Sandmaier, Brenda M., Savani, Bipin N., Seo, Sachiko, Shah, Nirav N., Uy, Geoffrey L., Valcárcel, David, Verdonck, Leo F., Waller, Edmund K., Wang, Youjin, Weisdorf, Daniel, Wirk, Baldeep, Wong, Eric, Yared, Jean A., and Saber, Wael

Published
2020
Full Text
View/download PDF

17. Survival following allogeneic transplant in patients with myelofibrosis

Author

Gowin, Krisstina, Ballen, Karen, Ahn, Kwang Woo, Hu, Zhen-Huan, Ali, Haris, Arcasoy, Murat O., Devlin, Rebecca, Coakley, Maria, Gerds, Aaron T., Green, Michael, Gupta, Vikas, Hobbs, Gabriela, Jain, Tania, Kandarpa, Malathi, Komrokji, Rami, Kuykendall, Andrew T., Luber, Kierstin, Masarova, Lucia, Michaelis, Laura C., Patches, Sarah, Pariser, Ashley C., Rampal, Raajit, Stein, Brady, Talpaz, Moshe, Verstovsek, Srdan, Wadleigh, Martha, Agrawal, Vaibhav, Aljurf, Mahmoud, Angel Diaz, Miguel, Avalos, Belinda R., Bacher, Ulrike, Bashey, Asad, Beitinjaneh, Amer M., Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Cutler, Corey S., DeFilipp, Zachariah, Gadalla, Shahinaz M., Ganguly, Siddhartha, Grunwald, Michael R., Hashmi, Shahrukh K., Kharfan-Dabaja, Mohamed A., Kindwall-Keller, Tamila, Kröger, Nicolaus, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Marks, David I., Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Pawarode, Attaphol, Rowe, Jacob M., Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Tamari, Roni, Verdonck, Leo F., Yared, Jean A., Alyea, Edwin, Popat, Uday, Sobecks, Ronald, Scott, Bart L., Nakamura, Ryotaro, Mesa, Ruben, and Saber, Wael

Published
2020
Full Text
View/download PDF

20. A Phase 2 Trial of CD24Fc for Prevention of Graft-vs-Host Disease

Author

Magenau, John M, primary, Jaglowski, Samantha M, additional, Uberti, Joseph, additional, Farag, Sherif S, additional, Mansour Riwes, Mary, additional, Pawarode, Attaphol, additional, Anand, Sarah, additional, Ghosh, Monalisa, additional, Maciejewski, John, additional, Braun, Thomas M, additional, Devenport, Martin, additional, Lu, Susan, additional, Banerjee, Bhramori, additional, DaSilva, Carolyn, additional, Devine, Steven M, additional, Zhang, Mei-Jie, additional, Burns, Linda J, additional, Liu, Yang, additional, Zheng, Pan, additional, and Reddy, Pavan, additional

Published
2023
Full Text
View/download PDF

21. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research

Author

Murthy, Hemant S., Ahn, Kwang Woo, Estrada-Merly, Noel, Alkhateeb, Hassan B., Bal, Susan, Kharfan-Dabaja, Mohamed A., Dholaria, Bhagirathbhai, Foss, Francine, Gowda, Lohith, Jagadeesh, Deepa, Sauter, Craig, Abid, Muhammad Bilal, Aljurf, Mahmoud, Awan, Farrukh T., Bacher, Ulrike, Badawy, Sherif M., Battiwalla, Minoo, Bredeson, Chris, Cerny, Jan, Chhabra, Saurabh, Deol, Abhinav, Diaz, Miguel Angel, Farhadfar, Nosha, Freytes, César, Gajewski, James, Gandhi, Manish J., Ganguly, Siddhartha, Grunwald, Michael R., Halter, Joerg, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Jimenez-Jimenez, Antonio Martin, Kalaycio, Matt, Kamble, Rammurti, Krem, Maxwell M., Lazarus, Hillard M., Lazaryan, Aleksandr, Maakaron, Joseph, Munshi, Pashna N., Munker, Reinhold, Nazha, Aziz, Nishihori, Taiga, Oluwole, Olalekan O., Ortí, Guillermo, Pan, Dorothy C., Patel, Sagar S., Pawarode, Attaphol, Rizzieri, David, Saba, Nakhle S., Savani, Bipin, Seo, Sachiko, Ustun, Celalettin, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Wirk, Baldeep, Oran, Betul, Nakamura, Ryotaro, Scott, Bart, and Saber, Wael

Published
2022
Full Text
View/download PDF

22. MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD

Author

Major-Monfried, Hannah, Renteria, Anne S., Pawarode, Attaphol, Reddy, Pavan, Ayuk, Francis, Holler, Ernst, Efebera, Yvonne A., Hogan, William J., Wölfl, Matthias, Qayed, Muna, Hexner, Elizabeth O., Wudhikarn, Kitsada, Ordemann, Rainer, Young, Rachel, Shah, Jay, Hartwell, Matthew J., Chaudhry, Mohammed S., Aziz, Mina, Etra, Aaron, Yanik, Gregory A., Kröger, Nicolaus, Weber, Daniela, Chen, Yi-Bin, Nakamura, Ryotaro, Rösler, Wolf, Kitko, Carrie L., Harris, Andrew C., Pulsipher, Michael, Reshef, Ran, Kowalyk, Steven, Morales, George, Torres, Ivan, Özbek, Umut, Ferrara, James L.M., and Levine, John E.

Published
2018
Full Text
View/download PDF

23. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia

Author

Hogan, William, Battiwalla, Minoo, Copelan, Edward, Hildebrandt, Gerhard, Ganguly, Sid, Majhail, Navneet, Woolfrey, Ann, Nivison-Smith, Ian, Hertzberg, Mark, Diaz, Miguel Angel, Jakubowski, Ann, Ustun, Celalettin, Yong, Agnes, Freytes, Cesar, DeFilipp, Zachariah, Inamoto, Yoshi, Cahn, Jean-Yves, Savani, Bipin, Yared, Jean, Bajel, Ashish, Bacher, Ulrike, Uy, Geoffrey, Rizzieri, David, Wieduwilt, Matthew, Schultz, Kirk, Grunwald, Michael, Kamble, Rammurti, Qayed, Muna, Brammer, Jonathan, Ballen, Karen, Khera, Nandita, Schouten, Harry, Bierings, Marc, Kanakry, Christopher, Wood, William Allen, Saad, Ayman, Savoie, Lynn, Hamilton, Betty Ky, Aljurf, Mahmoud, Vij, Ravi, Pawarode, Attaphol, Olsson, Richard, Wirk, B. Mona, Beitinjaneh, Amer, Seo, Sachiko, Cerny, Jan, Akpek, Gorgun, Norkin, Maxim, Nishihori, Taiga, Lazaryan, Aleksandr, Sabloff, Mitchell, Kebriaei, Partow, Anasetti, Claudio, Zhang, Mei-Jie, Wang, Hai-Lin, Aldoss, Ibrahim, de Lima, Marcos, Khoury, H. Jean, Sandmaier, Brenda M., Horowitz, Mary M., Artz, Andrew, Bejanyan, Nelli, Ciurea, Stefan, Lazarus, Hillard M., Gale, Robert Peter, Litzow, Mark, Bredeson, Christopher, Seftel, Matthew D., Pulsipher, Michael A., Boelens, Jaap-Jan, Alvarnas, Joseph, Champlin, Richard, Forman, Stephen, Pullarkat, Vinod, Weisdorf, Daniel, and Marks, David I.

Published
2018
Full Text
View/download PDF

26. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Author

Muffly, Lori, Pasquini, Marcelo C., Martens, Michael, Brazauskas, Ruta, Zhu, Xiaochun, Adekola, Kehinde, Aljurf, Mahmoud, Ballen, Karen K., Bajel, Ashish, Baron, Frederic, Battiwalla, Minoo, Beitinjaneh, Amer, Cahn, Jean-Yves, Carabasi, Mathew, Chen, Yi-Bin, Chhabra, Saurabh, Ciurea, Stefan, Copelan, Edward, D'Souza, Anita, Edwards, John, Foran, James, Freytes, Cesar O., Fung, Henry C., Gale, Robert Peter, Giralt, Sergio, Hashmi, Shahrukh K., Hildebrandt, Gerhard C., Ho, Vincent, Jakubowski, Ann, Lazarus, Hillard, Luskin, Marlise R., Martino, Rodrigo, Maziarz, Richard, McCarthy, Philip, Nishihori, Taiga, Olin, Rebecca, Olsson, Richard F., Pawarode, Attaphol, Peres, Edward, Rezvani, Andrew R., Rizzieri, David, Savani, Bipin N., Schouten, Harry C., Sabloff, Mitchell, Seftel, Matthew, Seo, Sachiko, Sorror, Mohamed L., Szer, Jeff, Wirk, Baldeep M., Wood, William A., and Artz, Andrew

Published
2017
Full Text
View/download PDF

28. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes

Author

Oran, Betül, Ahn, Kwang Woo, Fretham, Caitrin, Beitinjaneh, Amer, Bashey, Asad, Pawarode, Attaphol, Wirk, Baldeep, Scott, Bart L., Savani, Bipin N., Bredeson, Christopher, Weisdorf, Daniel, Marks, David I., Rizzieri, David, Copelan, Edward, Hildebrandt, Gerhard C., Hale, Gregory A., Murthy, Hemant S., Lazarus, Hillard M., Cerny, Jan, Liesveld, Jane L., Yared, Jean A., Yves-Cahn, Jean, Szer, Jeffrey, Verdonck, Leo F., Aljurf, Mahmoud, van der Poel, Marjolein, Litzow, Mark, Kalaycio, Matt, Grunwald, Michael R., Diaz, Miguel Angel, Sabloff, Mitchell, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Farhadfar, Nosha, Reshef, Ran, Olsson, Richard F., Gale, Robert Peter, Nakamura, Ryotaro, Seo, Sachiko, Chhabra, Saurabh, Hashmi, Shahrukh, Farhan, Shatha, Ganguly, Siddhartha, Nathan, Sunita, Nishihori, Taiga, Jain, Tania, Agrawal, Vaibhav, Bacher, Ulrike, Popat, Uday, and Saber, Wael

Published
2021
Full Text
View/download PDF

30. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

Author

Epperla, Narendranath, Ahn, Kwang W., Litovich, Carlos, Ahmed, Sairah, Battiwalla, Minoo, Cohen, Jonathon B., Dahi, Parastoo, Farhadfar, Nosha, Farooq, Umar, Freytes, Cesar O., Ghosh, Nilanjan, Haverkos, Bradley, Herrera, Alex, Hertzberg, Mark, Hildebrandt, Gerhard, Inwards, David, Kharfan-Dabaja, Mohamed A., Khimani, Farhad, Lazarus, Hillard, Lazaryan, Aleksandr, Lekakis, Lazaros, Murthy, Hemant, Nathan, Sunita, Nishihori, Taiga, Pawarode, Attaphol, Prestidge, Tim, Ramakrishnan, Praveen, Rezvani, Andrew R., Romee, Rizwan, Shah, Nirav N., Sureda, Ana, Fenske, Timothy S., and Hamadani, Mehdi

Published
2019
Full Text
View/download PDF

31. Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis

Author

Ragon, Brittany Knick, primary, Shah, Mithun Vinod, additional, D'Souza, Anita, additional, Estrada-Merly, Noel, additional, Gowda, Lohith, additional, George, Gemlyn, additional, DeLima, marcos, additional, Hashmi, Shahrukh, additional, Kharfan-Dabaja, Mohamed A, additional, Majhail, Navneet S, additional, Banerjee, Rahul, additional, Saad, Ayman, additional, Hildebrandt, Gerhard C., additional, Mian, Hira, additional, Abid, Muhammad Bilal, additional, Battiwalla, Minoo, additional, Lekakis, Lazaros J., additional, Patel, Sagar S., additional, Murthy, Hemant S., additional, Nieto, Yago, additional, Strouse, Christopher S, additional, Badawy, Sherif M., additional, Al Hadidi, Samer AI, additional, Dholaria, Bhagirathbhai, additional, Aljurf, Mahmoud, additional, Vesole, David H, additional, Lee, Cindy H, additional, Pawarode, Attaphol, additional, Gergis, Usama, additional, Miller, Kevin Charles, additional, Holmberg, Leona A, additional, Afrough, Aimaz, additional, Solh, Melhem M, additional, Munshi, Pashna, additional, Nishihori, Taiga, additional, Anderson, Larry D., additional, Wirk, Baldeep, additional, Kaur, Gurbakhash, additional, Qazilbash, Muzaffar H, additional, Shah, Nina, additional, Kumar, Shaji K, additional, and Usmani, Saad Z., additional

Published
2023
Full Text
View/download PDF

32. A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care (SOC) Versus Placebo Plus SOC in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (E-CELERATE; NCT05181540): Trial in Progress

Author

Scordo, Michael, primary, Shouse, Geoffrey, additional, Mountjoy, Luke, additional, Gauthier, Jordan, additional, Mulroney, Carolyn, additional, Dholaria, Bhagirathbhai, additional, Rowley, Scott D., additional, Pantin, Jeremy, additional, DeFilipp, Zachariah, additional, Mead, Monica, additional, Pawarode, Attaphol, additional, Qazilbash, Muzaffar H., additional, Beitinjaneh, Amer, additional, Bubalo, Joseph, additional, Khanal, Rashmi, additional, Abedi, Mehrdad, additional, and Finnegan, Paul, additional

Published
2023
Full Text
View/download PDF

34. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies

Author

Pasquini, Marcelo C., Zhang, Mei-Jie, Medeiros, Bruno C., Armand, Philippe, Hu, Zhen-Huan, Nishihori, Taiga, Aljurf, Mahmoud D., Akpek, Görgün, Cahn, Jean-Yves, Cairo, Mitchell S., Cerny, Jan, Copelan, Edward A., Deol, Abhinav, Freytes, César O., Gale, Robert Peter, Ganguly, Siddhartha, George, Biju, Gupta, Vikas, Hale, Gregory A., Kamble, Rammurti T., Klumpp, Thomas R., Lazarus, Hillard M., Luger, Selina M., Liesveld, Jane L., Litzow, Mark R., Marks, David I., Martino, Rodrigo, Norkin, Maxim, Olsson, Richard F., Oran, Betul, Pawarode, Attaphol, Pulsipher, Michael A., Ramanathan, Muthalagu, Reshef, Ran, Saad, Ayman A., Saber, Wael, Savani, Bipin N., Schouten, Harry C., Ringdén, Olle, Tallman, Martin S., Uy, Geoffrey L., Wood, William A., Jr., Wirk, Baldeep, Pérez, Waleska S., Batiwalla, Minoo, and Weisdorf, Daniel J.

Published
2016
Full Text
View/download PDF

35. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series

Author

Pawarode, Attaphol, Mineishi, Shin, Reddy, Pavan, Braun, Thomas M., Khaled, Yasser A., Choi, Sung W., Magenau, John M., Harris, Andrew C., Connelly, James A., Kitko, Carrie L., Parkin, Brian L., Goldstein, Steven C., Yanik, Gregory A., Levine, John E., Ferrara, James L., and Couriel, Daniel R.

Published
2016
Full Text
View/download PDF

36. Etanercept plus Topical Corticosteroids as Initial Therapy for Grade One Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Author

Gatza, Erin, Braun, Thomas, Levine, John E., Ferrara, James L.M., Zhao, Shuang, Wang, Tianyi, Chang, Lawrence, Harris, Andrew, Pawarode, Attaphol, Kitko, Carrie, Magenau, John M., Yanik, Gregory A., Couriel, Daniel R., Goldstein, Steven, Connelly, James, Reddy, Pavan, Paczesny, Sophie, and Choi, Sung Won

Published
2014
Full Text
View/download PDF

38. Use of Siltuximab for the Treatment of Severe Immune Effector Cell Neurotoxicity Syndrome Following Chimeric Antigen Receptor T-Cell Therapy: Single Center Case Series

Author

Geer, Marcus J., primary, Frame, David, additional, Magenau, John, additional, Maciejewski, John, additional, Anand, Sarah, additional, Riwes, Mary Mansour, additional, Pawarode, Attaphol, additional, Reddy, Pavan, additional, Scappaticci, Gianni B., additional, Markstrom, Denise, additional, and Ghosh, Monalisa, additional

Published
2022
Full Text
View/download PDF

41. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improves Transplant Outcomes in Older MDS Patients

Author

Oran, Betul, Ahn, Kwang Woo, Fretham, Caitrin, Beitinjaneh, Amer, Bashey, Asad, Pawarode, Attaphol, Wirk, Baldeep, Scott, Bart L, Savani, Bipin N, Bredeson, Christopher, Weisdorf, Daniel, Marks, David I, Rizzieri, David, Copelan, Edward, Hildebrandt, Gerhard C, Hale, Gregory A., Murthy, Hemant S, Lazarus, Hillard M, Cerny, Jan, Liesveld, Jane L, Yared, Jean A, Yves-Cahn, Jean, Szer, Jeffrey, Verdonck, Leo F, Aljurf, Mahmoud, van der Poel, Marjolein, Litzow, Mark, Kalaycio, Matt, Grunwald, Michael R, Diaz, Miguel Angel, Sabloff, Mitchell, Kharfan-Dabaja, Mohamed A, Majhail, Navneet S, Farhadfar, Nosha, Reshef, Ran, Olsson, Richard F, Gale, Robert Peter, Nakamura, Ryotaro, Seo, Sachiko, Chhabra, Saurabh, Hashmi, Shahrukh, Farhan, Shatha, Ganguly, Siddhartha, Nathan, Sunita, Nishihori, Taiga, Jain, Tania, Agrawal, Vaibhav, Bacher, Ulrike, Popat, Uday, and Saber, Wael

Subjects
Transplantation Conditioning, Myelodysplastic Syndromes, Graft vs Host Disease, Humans, Middle Aged, Busulfan, Melphalan, Survival Analysis, Article, Vidarabine, Aged
Abstract

Reduced-intensity conditioning (RIC) regimens developed to extend allogeneic stem cell transplantation (HSCT) to older patients have resulted in encouraging outcomes. We aimed to compare the two most commonly used RIC regimens, intravenous use of fludarabine with busulfan (FluBu) and fludarabine with melphalan (FluMel), in myelodysplastic syndrome (MDS). Through CIBMTR, we identified 1045 MDS patients aged ≥ 60 years who underwent first HSCT with a matched related or matched (8/8) unrelated donor using RIC. CIBMTR’s definition of RIC was used: a regimen that incorporated an intravenous busulfan total dose ≤ 7.2 mg/kg, or a low-dose melphalan total dose of ≤ 150 mg/m(2). The two groups, FluBu (n=697) and FluMel (n=448), were comparable for disease and transplant-related characteristics except for the more frequent use of anti-thymocyte globulin or alemtuzumab in the FluBu group (39% vs. 31%). The median age was 67 in both groups. FluMel was associated with a reduced relapse incidence (RI) compared with FluBu, with a 1-year adjusted incidence of 26% vs. 44% (p≤0.0001). Transplant-related mortality (TRM) was higher with FluMel compared with FluBu (26% vs. 16%, p≤0.0001). Since the magnitude of improvement with FluMel in RI was greater than the improvement in TRM with FluBu, disease-free survival (DFS) was improved at 1-year and beyond with FluMel compared with FluBu (48% vs. 40% at 1 year, p=0.02, and 35% vs. 27% at 3 years, p=0.01). Overall survival (OS) was comparable at 1 year (63% vs. 61%, p=0.4) but significantly improved with FluMel compared with FluBu at 3 years (46% vs. 39%, p=0.03). Our results suggest that FluMel is associated with superior DFS compared with FluBu due to reduced RI in older MDS patients.

Published
2021

42. Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT)

Author

Scordo, Michael, primary, Budde, Lihua E, additional, Abedi, Mehrdad, additional, Mulroney, Carolyn, additional, Fakhri, Bita, additional, Pawarode, Attaphol, additional, Dholaria, Bhagirathbhai, additional, Kavalerchik, Edward, additional, Aggarwal, Sanjay K., additional, Qazilbash, Muzaffar H., additional, Finnegan, Paul, additional, and Giralt, Sergio A., additional

Published
2020
Full Text
View/download PDF

43. 184 - A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care (SOC) Versus Placebo Plus SOC in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (E-CELERATE; NCT05181540): Trial in Progress

Author

Scordo, Michael, Shouse, Geoffrey, Mountjoy, Luke, Gauthier, Jordan, Mulroney, Carolyn, Dholaria, Bhagirathbhai, Rowley, Scott D., Pantin, Jeremy, DeFilipp, Zachariah, Mead, Monica, Pawarode, Attaphol, Qazilbash, Muzaffar H., Beitinjaneh, Amer, Bubalo, Joseph, Khanal, Rashmi, Abedi, Mehrdad, and Finnegan, Paul

Published
2023
Full Text
View/download PDF

44. Mitigating Damage Response with CD24 Fusion Protein for Prevention of Acute Graft-Versus-Host Disease

Author

Magenau, John M., primary, Jaglowski, Samantha, additional, Farag, Sherif S., additional, Uberti, Joseph, additional, Pawarode, Attaphol, additional, Riwes, Mary M., additional, Braun, Thomas, additional, Ghosh, Monalisa, additional, Anand, Sarah, additional, Maciejewski, John, additional, Yanik, Gregory A., additional, Choi, Sung, additional, Zheng, Pan, additional, Liu, Yang, additional, Devine, Steven M., additional, and Reddy, Pavan, additional

Published
2020
Full Text
View/download PDF

45. Targeting Danger Associated Molecular Pattern (DAMP) with CD24Fc to Reduce Acute Gvhd: Study Design on a Randomized Double Blind Placebo Controlled Phase III Clinical Trial (CATHY Study)

Author

Zheng, Pan, primary, Liu, Yang, additional, Chen, Hegang, additional, Devenport, Martin, additional, Reddy, Pavan, additional, Farag, Sherif S., additional, Devine, Steven M., additional, Jaglowski, Samantha, additional, Uberti, Joseph, additional, Braun, Thomas, additional, Yanik, Gregory A., additional, Choi, Sung, additional, Riwes, Mary M., additional, Maciejewski, John, additional, Pawarode, Attaphol, additional, Anand, Sarah, additional, Ghosh, Monalisa, additional, and Magenau, John M., additional

Published
2020
Full Text
View/download PDF

46. Rational Modification of Intestinal Microbiome and Metabolites after Allogeneic Hematopoietic Stem Cell Transplantation with Resistant Starch: A Pilot Study

Author

Riwes, Mary Mansour, primary, Schmidt, Alexander, additional, Braun, Thomas, additional, Magenau, John M., additional, Pawarode, Attaphol, additional, Parkin, Brian, additional, Anand, Sarah, additional, Ghosh, Monalisa, additional, Maciejewski, John, additional, King, Darren, additional, Tewari, Muneesh, additional, Choi, Sung W., additional, Yanik, Gregory A., additional, Maccready, Kristi, additional, Schmidt, Thomas, additional, and Reddy, Pavan, additional

Published
2019
Full Text
View/download PDF

50. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report

Author

Kim, Haesook T., primary, Ahn, Kwang Woo, additional, Hu, Zhen-Huan, additional, Davids, Matthew S., additional, Volpe, Virginia O., additional, Antin, Joseph H., additional, Sorror, Mohamed L., additional, Shadman, Mazyar, additional, Press, Oliver, additional, Pidala, Joseph, additional, Hogan, William, additional, Negrin, Robert, additional, Devine, Steven, additional, Uberti, Joseph, additional, Agura, Edward, additional, Nash, Richard, additional, Mehta, Jayesh, additional, McGuirk, Joseph, additional, Forman, Stephen, additional, Langston, Amelia, additional, Giralt, Sergio A., additional, Perales, Miguel-Angel, additional, Battiwalla, Minoo, additional, Hale, Gregory A., additional, Gale, Robert Peter, additional, Marks, David I., additional, Hamadani, Mehdi, additional, Ganguly, Sid, additional, Bacher, Ulrike, additional, Lazarus, Hillard, additional, Reshef, Ran, additional, Hildebrandt, Gerhard C., additional, Inamoto, Yoshihiro, additional, Cahn, Jean-Yves, additional, Solh, Melhem, additional, Kharfan-Dabaja, Mohamed A., additional, Ghosh, Nilanjan, additional, Saad, Ayman, additional, Aljurf, Mahmoud, additional, Schouten, Harry C., additional, Hill, Brian T., additional, Pawarode, Attaphol, additional, Kindwall-Keller, Tamila, additional, Saba, Nakhle, additional, Copelan, Edward A., additional, Nathan, Sunita, additional, Beitinjaneh, Amer, additional, Savani, Bipin N., additional, Cerny, Jan, additional, Grunwald, Michael R., additional, Yared, Jean, additional, Wirk, Baldeep M., additional, Nishihori, Taiga, additional, Chhabra, Saurabh, additional, Olsson, Richard F., additional, Bashey, Asad, additional, Gergis, Usama, additional, Popat, Uday, additional, Sobecks, Ronald, additional, Alyea, Edwin, additional, Saber, Wael, additional, and Brown, Jennifer R., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results